MedTrace Logo

Dexmedetomidine vs Lignocaine for Reducing Intubation-Induced Hemodynamic Responses in Cardiac Surgery: A Randomized Controlled Trial

NCT07611890 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 70

Last updated 2026-05-28

No results posted yet for this study

Summary

After confirming eligibility, written informed consent will be obtained by a trained team member who is not involved in assigning treatment or giving the study medication. Each participant will receive a unique study number to protect privacy. Participants will be randomly assigned to receive one of the study medications using a chance-based method.The study medication will be administered through a vein before placement of the breathing tube. Blood pressure and pulse rate will be measured before the procedure and at several time points after the breathing tube is inserted.

Conditions

  • Laryngoscopic Stress Response
  • Dexmedetomidine
  • Lignocaine

Interventions

DRUG

IV dexmedetomidine

0.5 Mcg/kg of Dexmedetomidine will be given 10 minutes before laryngoscopy

DRUG

IV Lignocaine

Patients will be given 1.5 mg/kg of Lignocaine 3 minutes before laryngoscopy

Sponsors & Collaborators

  • Rawalpindi Institute of Cardiology

    lead OTHER

Principal Investigators

  • Qudsia Anjum, MBBS,FCPS · Rawalpindi Institute of Cardiology

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-05-21
Primary Completion
2026-08-21
Completion
2026-08-21

Countries

  • Pakistan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07611890 on ClinicalTrials.gov